太美医疗科技

Zhejiang Taimei Medical Technology Co., Ltd.
浙江太美醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2576)

ANNOUNCEMENT OF THE RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024

The board of directors of Zhejiang Taimei Medical Technology Co., Ltd. hereby announces the audited consolidated annual results of the Group for the year ended December 31, 2024, together with the comparative figures for the year ended December 31, 2023. The consolidated financial statements for the year ended December 31, 2024, have been audited by the Group's external auditor, PricewaterhouseCoopers, in accordance with International Standards on Auditing, and have also been reviewed by the Audit Committee.

FINANCIAL HIGHLIGHTS

	Year Ended December 31,				
	2024		2023		
	RMB'000	***% of Revenue***	*RMB'000*	*% of Revenue*	*Year-on-year change (%)*
Revenue	**551,156**	**100.0**	573,137	100.0	(3.8)
Gross profit	**224,943**	**40.8**	179,002	31.2	25.7
Operating loss	**(252,452)**	**(45.8)**	(396,587)	(69.2)	(36.3)
Loss for the year	**(217,405)**	**(39.4)**	(356,379)	(62.2)	(39.0)
Adjusted net loss (non-IFRS measure)[1]	**(57,260)**	**(10.4)**	(317,066)	(55.3)	(81.9)

(1) See the section headed "Adjusted net loss (non-IFRS measure)" for more information about the non-IFRS Accounting Standards measures.

MANAGEMENT DISCUSSION AND ANALYSIS

(I) BUSINESS OVERVIEW

The Company, as a digital intelligence platform for life sciences, is engaged in business operations across areas such as pharmaceutical research and development, pharmacovigilance, and pharmaceutical commercialization. Besides our independent and complete line of professional software products, the Company has innovatively developed the "Trials Intelligent Clinical Research Collaboration Platform" and the "Wujie Enterprise-Medical Academic Interaction Platform", which fosters connections among various industry participants, including pharmaceutical companies, hospitals (research centers), third-party service providers (including CRO, SMO, etc.), doctors, and patients, etc. Integrated with advanced technologies such as AI and cloud computing, the platforms enable standardized and unified data flow, process collaboration, and resource integration, and significantly improve the overall efficiency of pharmaceutical R&D and post-launch commercial performance, thereby enhancing multilateral values and mutual success. On our mission of "Unleashing the digitalization potential for ready health accessibility", the Company is building the infrastructure for the future operations of the pharmaceutical industry, which will accelerate the market entry of new drugs, ensure drug safety for patients, make high-quality drugs easily accessible, and reduce patients' medical burden.

In 2024, the Company launched a comprehensive upgrade of its digital intelligence platform, as integrated platforms gradually become a new demand in the digital transformation of the pharmaceutical industry. Our digitalized R&D and commercialization platforms are also undergoing a full upgrade, transitioning from TrialOS and PharmaOS to Trials and Wujie. The upgraded "Trials Intelligent Clinical Research Collaboration Platform" was selected by the Zhejiang Provincial Department of Economy and Information Technology as one of the 2024 Zhejiang Provincial Outstanding Cases in Digital Economy Development. As the Wujie Platform has officially released its enterprise-end and doctor-end products, all related features will be progressively rolled out. Concurrently, we are assisting pharmaceutical companies in building their own digital integration platforms. In 2024, we successfully completed the first phase of Client A's Clinical Operations Integrated Platform, which achieves the integration and intelligent analysis of clinical operations management workflows, document flows, and data flows to enhance the efficiency of its clinical trial management.

In 2024, the Company focused on its core competitive products and committed to improving internal operational efficiency and profitability. In 2024, our overall business remained stable, with a significant increase in gross profit margin and a substantial decrease in both the net loss and the adjusted net loss compared to last year. In 2024, the Group's total revenue amounted to RMB551.2 million, with a gross profit margin of 40.8%, representing an increase of 9.6 percentage points as compared to 31.2% in 2023, which is a significant improvement in gross profit margin. Our loss for the year decreased from RMB356.4 million in 2023 to RMB217.4 million in 2024, representing a year-on-year decrease of 39.0% in loss. Excluding listing expenses related to the Global Offering in 2024 and equity-based payments, the adjusted net loss amounted to RMB57.3 million, representing a year-on-year decrease of 81.9%.

In March 2024, Taimei Medical Technology published its AI technology application case in clinical trial collection and analysis in Nature, a renowned international academic journal.

As at December 31, 2024, we provided services to over 1,400 pharmaceutical companies and CROs, including 21 out of the top 25 global pharmaceutical companies and 90 companies listed in the "2024 Top 100 Chinese Pharmaceutical Innovative Enterprises". In terms of number of customers, we have become the most widely adopted digital solution provider for pharmaceutical and medical device R&D and commercialization in China.

Our Industry Solutions

Our solutions for the pharmaceutical and medical device industry consist of cloud-based software, including SaaS products and customized products, and digital services. Our SaaS products and digital services are primarily offered through digital collaboration platforms, including "Trials Intelligent Clinical Research Collaboration Platform" and the "Wujie Enterprise-Medical Academic Interaction Platform", while our customized products are mainly hosted on a private cloud, in-house infrastructure, rather than through "Trials Intelligent Clinical Research Collaboration Platform" and the "Wujie Enterprise-Medical Academic Interaction Platform". The following diagram illustrates our main products and services:



Digital Collaboration Platforms

Our industry solutions is based on the digital collaboration platform for pharmaceutical and medical device research and development, the "Trials Intelligent Clinical Research Collaboration Platform", and the digital collaboration platform for pharmaceutical and medical device commercialization, the "Wujie Enterprise-Medical Academic Interaction Platform". Staff from pharmaceutical companies, hospitals, CROs/SMOs and other relevant parties can easily manage and use our cloud-based software products and digital services through a unified landing page on the platforms, access the latest information and collaborate online. The underlying technology of our platforms breaks the boundaries between organizations and supports data interoperability among different software products and digital services, enabling efficient R&D and commercialization of innovative drugs and medical devices. The "Trials Intelligent Clinical Research Collaboration Platform", with its new client-side interface and conversation-based interaction, will deliver a more intuitive user experience and facilitate rapid collaboration, further breaking down artificial barriers between different software and services, orienting itself towards users' needs for external collaboration and process management. The "Wujie Enterprise-Medical Academic Interaction Platform" is expected to achieve easier, more efficient, direct and compliant interaction between pharmaceutical companies and physicians by integrating online channels.

Cloud-based Software

Based on our digital collaboration platforms, we have built a series of software for different types of organizations and roles and covering critical use cases in pharmaceutical and medical device R&D and commercialization. For instance, our software facilitates the planning, tracking and monitoring of site and trial-related activities, and streamlines the management and filing of clinical research documents. Our software can also be used for patient recruitment, patient follow-up, data collection and analysis, as well as sales relationship management, to address the challenges faced by industry participants and improve workflow efficiency. The software that we offer are hosted by a cloud service provider and offered to customers via cloud service, instead of running locally on our customers' devices with no network connection. We offer our SaaS products through the "Trials Intelligent Clinical Research Collaboration Platform" or the "Wujie Enterprise-Medical Academic Interaction Platform", which leverage public cloud service to deliver our SaaS products via the internet across organizations. We also deliver our customized products primarily via private cloud service, which reside on a single organization's in-house infrastructure instead of utilizing the "Trials Intelligent Clinical Research Collaboration Platform" or the "Wujie Enterprise-Medical Academic Interaction Platform".

For our cloud-based software, we generally recognize the revenue over the contract term since our delivery of products and in accordance with our customers' consumption of products or at a point of time when such product is delivered to and accepted by our customers. During the Track Record Period, the majority of our revenue from cloud-based software was derived from SaaS products.

In 2024, 37.9% of our revenue was generated from the sales of our cloud-based software. For our SaaS products, generally, we recognize the revenue over the contract term since our delivery of products and in accordance with our customers' consumption of products.

Digital Services

Based on our understanding of the industry and to better cater to the demands of different types of customers, we also provide our customers with a range of digital services, primarily assisting IRC, achieving efficient SMO resource distribution and execution, offering pharmacovigilance services and other services to support our customers' R&D and commercialization activities. These digital services are based on our digital collaboration platforms and linked with SaaS products to enable online operation, monitoring and management for improved efficiency and quality. By offering digital services, we further accumulate industry knowledge and insights, which helps enhance our capability to optimize our platforms and software products.

By choosing our digital services, our customers can leverage our service personnel who are well-versed in our software to fulfill their needs with consistent quality and no additional staff overhead. Our IRC service primarily helps pharmaceutical and medical device companies conduct independent reading of medical images. In the meantime, our digital clinical research services include digital SMO business management, which offers integrated service related to training, management, and supervision of SMO service delivery, pharmacovigilance service, and also digital clinical trial services, which enable digitally decomposing and streamlining operations of clinical research for quality, transparency, and efficiency, and realize real-time risk alerts and achieves digital project management. These digital services typically integrate the capabilities of our corresponding cloud-based software and platforms, and therefore our customers would typically also be paid users of the corresponding cloud-based software, though our customers can also use some of our digital services without becoming paid users of our cloud-based software. For example, per customer request, the Company occasionally delivered pharmacovigilance service without leveraging our software.

In 2024, 62.1% of our revenue was generated from the provision of digital services. For our digital services, we recognize revenue over contract term since our delivery of services and in accordance with the progress of our service obligation performance.

(II) BUSINESS OUTLOOK AND PROSPECTS

Driven by both the accelerating AI technology evolution and the industrial digital transformation, the Company is standing at the cusp of new transformation and intelligent upgrading. To achieve the vision of "Unleashing the digitalization potential for ready health accessibility" based on our artificial intelligence strategy, the Company strive to create new growth momentum by mainly taking the following key measures in the future:

Launch an intelligent platform for clinical research

The platform is expected to have the following features:

1. The platform emphasizes AI genetics, covering the entire chain from cognition to reasoning and optimization, achieving self-evolution in clinical research; 2. The platform deeply integrates dynamic learning algorithms (i.e. DLA model), multimodal data fusion technology, and full-process automated decision-making engines, aiming to reconstruct the intelligent paradigm for clinical trial design, execution, and analysis; 3. The platform utilizes research full-chain data as the core driving force, providing end-to-end AI solutions from intelligent scheme design, proactive risk forecast, autonomous data management to adaptive statistical analysis, based on training data of over 4,000 historical trials and real-time feedback optimization mechanisms; 4. By integrating with the Trials platform of Taimei Medical Technology and upgrading the platform to the iTrial intelligent system, "Literary Intelligence" will realize the closed loop of "perception-decision-execution-evolution" in clinical research, becoming the world's first clinical research dedicated AI engine with cross-disease migration learning and self-optimization capabilities, empowering pharmaceutical companies, CROs, and researchers to reduce R&D costs by 30%, increase trial efficiency by 50%, driving the transition of new drug development from "experience-driven" to "wisdom-driven co-creation".

Continue to update and expand our products and services

We will leverage industry insights and digital technology to standardize more clinical services and enrich our product portfolio in the pharmaceutical and medical device R&D and commercialization areas. We offer comprehensive one-stop solutions, catering to companies of all sizes to meet their diverse needs in the pharmaceutical and medical device industry. We expect to expand our products and services, including incorporating global project operations, risk management, medical writing, and knowledge accumulation and application, to provide a better user experience.

Drawing on our expertise in data security and compliance, we will adopt advanced technologies such as multi-cloud deployment and containerization technology, as well as cloud computing security measures, to improve our offerings. These initiatives will adapt our products to the ever-evolving IT infrastructure of global pharmaceutical and medical device companies, enabling us to provide secure and compliant solutions to meet developing industry needs.

Expand customer base and build a cooperative ecosystem with clients

We will refine our direct sales model and promotion strategies to broaden our customer base. Leveraging our established brand reputation, we will implement targeted marketing strategies to reach a wider pool of high-quality potential customers. Our targeted marketing initiatives will be tailored to address the specific needs of potential clients, showcasing the value our solutions bring to their unique challenges to ensure a more effective outreach.

We believe that our ability to attract new customers ultimately rests on our capacity to deliver high-quality software and digital services. Our comprehensive product portfolio empowers us to showcase how our offerings streamline operations, heighten efficiency, and deliver exceptional outcomes. By swiftly addressing industry pain points and meeting underserved needs, we will continue to optimize our products (including AI evolution driven by customer needs, where we refine high-frequency requirements from customers' work order systems to rapidly generate AI solution models; and customers' collaborative development modes, where we jointly establish AI laboratories in the vertical sector with top biopharmaceutical companies, sharing intellectual property rights) to align with customer demands, solidifying our role as a trusted partner in their digital transformation journey.

At the same time, the Company intends to expand its customer base and build a cooperative ecosystem with customers. In this regard, the Company is extensively engaged with leading biopharmaceutical enterprises, serving 21 out of the world's top 25 pharmaceutical companies. We have supported a total of 40 NDA/BLA application projects in China, with our AI training dataset covering the entire lifecycle of new drugs. The high customer contract renewal rate ensures continuous data feedback, with an annual increase of over 200 new trial datasets, driving the quarterly iteration and upgrade of our DLA model.

Expand internationally and foster global collaboration

As Chinese pharmaceutical companies increasingly seek global expansion amid domestic industry growth and R&D advancements, we plan to provide global digital transformation solutions to assist both domestic and international teams in operating efficiently. Through these efforts, we aim to address our customers' digitalization needs for global multi-center clinical research, positioning ourselves as a one-stop digital service platform for Chinese pharmaceutical and medical device companies venturing into the international market.

To capitalize on the global momentum in pharmaceutical and medical device digitalization, we plan to develop international commercialization strategies tailored to overseas markets. Leveraging our early-mover advantage and technological capabilities, we will facilitate the construction of a global interconnected platform and offer advanced digital solutions to international pharmaceutical companies, thereby fostering global pharmaceutical and medical device innovation.

(III) FINANCIAL REVIEW

Revenue

	Year Ended December 31,				
	2024		2023		
	RMB'000	***% of Revenue***	*RMB'000*	*% of Revenue*	*Year-on-year change (%)*
Cloud-based Software					
– SaaS products	**161,926**	**29.4**	155,740	27.2	4.0
– Customized products	**46,685**	**8.5**	45,613	8.0	2.4
Subtotal	**208,611**	**37.9**	201,353	35.2	3.6
Digital Services	**342,512**	**62.1**	369,931	64.5	(7.4)
Others	**33**	**0.0**	1,853	0.3	(98.2)
Total	**551,156**	**100.0**	573,137	100.0	(3.8)

We primarily derive our revenue from (i) the sales of our cloud-based software, including SaaS products and customized products, as well as relevant technical support; and (ii) provision of digital services, primarily including digital clinical research services and IRC services.

Our revenue decreased by 3.8% from RMB573.1 million in 2023 to RMB551.2 million in 2024, which was the combined result of the decline of digital services and increase in cloud-based software.

Cloud-based Software. Our revenue from sales of cloud-based software increased by 3.6% from RMB201.4 million in 2023 to RMB208.6 million in 2024, which was primarily attributable to the increase in sales of the SaaS products from RMB155.7 million in 2023 to RMB161.9 million in 2024. The growth was attributed to our continuous product updates, strengthened cross-selling efforts, and a focused strategy on key customers. The revenue from customers using two or more SaaS products increased by 5.0% from RMB1.2 million to RMB1.3 million.

Digital services. Our revenue from digital services decreased by 7.4% from RMB369.9 million in 2023 to RMB342.5 million in 2024, mainly due to the intensified market competition, leading to lower average service price in 2024.

Cost of sales

Our cost of sales decreased by 17.2% from RMB394.1 million in 2023 to RMB326.2 million in 2024, primarily attributable to the optimization and adjustment of the product structure, the streamlining of operating procedures, and the improvement of labor efficiency.

Gross profit and gross margin

Our gross profit increased by 25.7% from RMB179.0 million in 2023 to RMB224.9 million in 2024. Our gross profit margin increased from 31.2% in 2023 to 40.8% in 2024, primarily due to our effective cost reduction strategy, which included the optimization and adjustment of the product structure, the streamlining of operating procedures, and the improvement to labor efficiency.

Selling expenses

Our selling expenses decreased by 41.7% from RMB150.2 million in 2023 to RMB87.6 million in 2024, primarily due to sales strategies with enhanced efficiency and streamlining personnel structure.

Administrative expenses

Our administrative expenses increased from RMB268.9 million in 2023 to RMB321.4 million in 2024, primarily due to a significant increase of RMB111.3 million in our share-based payments primarily related to the acquisition of certain indirect equity interests in a subsidiary of the Company, Taimei Intelligence Pharmaceutical (Shanghai) R&D Co., Ltd. ("太美智研醫藥研發(上海)有限公司", formerly named "聖方(上海)醫藥研發有限公司"), by certain Shareholders in January 2024. Such increase was partially offset by a decrease of RMB59.2 million in staff costs due to our efforts in optimizing management efficiency and streamlining personnel structure.

Research and development expenses

Our research and development expenses decreased by 48.5% from RMB169.2 million in 2023 to RMB87.1 million in 2024, primarily due to our optimizing R&D efficiency and streamlining personnel structure.

Net impairment losses on financial and contract assets

We recorded net impairment losses on financial and contract assets of RMB8.4 million in 2023 and RMB3.6 million in 2024. Such change was primarily due to a decrease in contract assets as we completed certain projects.

Net impairment losses on intangible assets

We recorded net impairment losses on intangible assets of RMB9.8 million in 2024, compared to RMB9.6 million in 2023 due to the impairment of the goodwill arising from the acquisitions of Shanghai Taimei Xinghuan Digital Technology Co., Ltd. ("上海太美星環數字科技有限公司", formerly named "上海軟素科技股份有限公司"), which is a wholly-owned subsidiary of the Company.

Other income

Our other income decreased from RMB19.4 million in 2023 to RMB18.0 million in 2024, primarily due to the decrease of RMB2.0 million in additional deductible input VAT.

Other gains – net

Our net other gains increased from RMB11.3 million in 2023 to RMB14.0 million in 2024. This change was primarily due to (i) an increase of RMB8.9 million in net foreign exchange gains, resulting from the fluctuations in the US$ to RMB exchange rate, (ii) partially offset by a provision for an outstanding litigation of RMB4.3 million and a decrease of RMB2.3 million in fair value gains on financial assets at fair value through profit or loss.

Finance income – net

Our net finance income decreased from RMB40.2 million in 2023 to RMB35.0 million in 2024 primarily due to a decrease of RMB5.9 million in interest income.

Loss for the year

As a result of the above, we recorded loss for the year of RMB217.4 million in 2024, compared to a loss for the year of RMB356.4 million in 2023.

Adjusted net loss (non-IFRS measure)

To supplement our consolidated financial statements, which are presented in accordance with IFRS, we also use adjusted net loss as an additional non-IFRS measure, which is not required by, or presented in accordance with, IFRS.

We define adjusted net loss (a non-IFRS measure) as the loss for the year adjusted by adding back share-based payments and listing expenses. We believe the presentation of this non-IFRS measure provides useful information to investors and management in facilitating a comparison of our operating performance from year to year by eliminating potential impacts of these items. However, our presentation of adjusted net loss may not be comparable to similarly titled measures presented by other companies. The use of this non-IFRS measure has limitations as an analytical tool, and you should not consider it in isolation from, or as a substitute for, an analysis of our results of operations or financial condition as reported under IFRS.

The tables below set forth the reconciliation of our non-IFRS measure presented in accordance with IFRS for the year ended December 31, 2024 indicated:

	Year Ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
Loss for the year	**(217,405)**	(356,379)
Adjustment:		
Share-based payments	**129,419**	13,292
– Share-based payments to employees	**36,583**	13,292
– Share-based compensation to certain shareholders	**92,836**	–
Listing expenses	**30,726**	26,021
– Listing expenses in connection with previous listing preparation	**–**	12,016
– Listing expenses in connection with the Global Offering	**30,726**	14,005
Adjusted net loss for the year (a non-IFRS measure)	**(57,260)**	(317,066)

Liquidity and capital resource

Our principal use of cash in 2024 was for working capital purposes. Our main source of liquidity has been generated from proceeds from our business operations, the net proceeds from the Global Offering, and bank borrowings. We do not anticipate any changes to the availability of financing to fund our operations in the future.

As at December 31, 2024, the Group had net current assets of RMB1,184.5 million (December 31, 2023: RMB968.3 million) of which cash and cash equivalents, short-term bank deposits, short-term treasury investments, and restricted cash were RMB319.3 million, RMB599.9 million, RMB159.4 million and RMB5.1 million (December 31, 2023: RMB517.9 million, RMB269.2 million, nil and RMB1.5 million), respectively. Total bank borrowing was RMB10.0 million (December 31, 2023: nil) which is repayable within one year.

As at December 31, 2024, the Group's current ratio[(1)] was 5.05 (December 31, 2023: 3.71) and gearing ratio[(2)] was 22.0% (December 31, 2023: 27.9%). The Group has sufficient cash to meet its working capital requirements. This strong cash position enables the Group to explore potential business development opportunities to expand in China and overseas.

Notes:

(1) Current ratio equals current assets divided by current liabilities as at the same date.

(2) Gearing ratio equals total liabilities divided by total assets and multiplied by 100% as at the same date.

Pledge of assets

As at December 31, 2024, the Group had no pledge of assets.

Exchange rate fluctuation risk

During the year ended December 31, 2024, the Group mainly operated in China with most of the transactions settled in Renminbi. The functional currency of the Company and the subsidiaries that operate in the PRC, and the subsidiaries operate in the the United States and Singapore are Renminbi, U.S. dollar and Singapore dollar, respectively. For the year ended December 31, 2024, we had currency translation losses of RMB4.3 million (2023: gains of RMB1.9 million) and net foreign exchange gains of RMB17.5 million (2023: gains of RMB8.6 million).

We did not hedge against any fluctuation in foreign currency during the year ended December 31, 2024.

Contingent liabilities

As at December 31, 2024, we did not have any material contingent liabilities.

Capital commitment

As at December 31, 2024, we did not have any material capital commitments.

Off-balance sheet commitments and arrangements

As at December 31, 2024, we had not entered into any off-balance sheet transactions.

Employees and remuneration

As at December 31, 2024, we had 627 full-time employees, of whom 619 were based in China, 4 were based in the United States and 4 were based in Singapore. The table below sets forth a breakdown of our full-time employees by function as at December 31, 2024:

Function	Number of Employees	% of Total
R&D	131	20.9
Sales and Marketing	85	13.5
Administrative	87	13.9
Professional and Technical Personnel	324	51.7
Total	**627**	**100.0**

Our total remuneration cost for the year ended December 31, 2024 was RMB363.9 million (2023: RMB595.2 million).

Use of proceeds from the Global Offering

The H Shares were first listed on the Main Board of the Stock Exchange on October 8, 2024. After deducting underwriting fees, commissions and other related listing expenses, the total net proceeds of the Global Offering amounted to approximately HK$259.5 million (the "**Net Proceeds**"). The Net Proceeds have been allocated and utilized in accordance with the intended purposes and proportions as set out in the prospectus of the Company dated September 27, 2024 during the Reporting Period.

The following table sets out the status of the use of the Net Proceeds and a summary of their utilization as at December 31, 2024 together with the expected timeline of use:

Intended use of net proceeds		Allocation of net proceeds	Approximate percentage of total Net Proceeds	Amount of net proceeds utilized up to December 31, 2024	Balance of net proceeds unutilized as at December 31, 2024	Intended timetable for use of the unutilized Net Proceeds(note)
(i)	To improve and upgrade our TrialOS Platform and PharmaOS Platform and their respective cloud-based software and digital services	HK$ 90.8 million	35%	HK$ 1.4 million	HK$ 89.4 million	Before December 31, 2029
(ii)	To improve our core technology and R&D capabilities	HK$ 77.9 million	30%	HK$ 2.1 million	HK$ 75.8 million	Before December 31, 2029
(iii)	To strengthen our sales and marketing capabilities	HK$ 26.0 million	10%	–	HK$ 26.0 million	Before December 31, 2029
(iv)	To selectively pursue strategic investments and acquisitions	HK$ 38.9 million	15%	–	HK$ 38.9 million	Before December 31, 2029
(v)	For our working capital and general corporate purposes	HK$ 25.9 million	10%	HK$ 1.8 million	HK$ 24.1 million	Before December 31, 2029
Total		HK$ 259.5 million	100%	HK$ 5.3 million	HK$ 254.2 million	

Note: The expected timeline to use the remaining proceeds is prepared based on the best estimate made by the Group, which is subject to change based on future developments and events which may be outside of the Group's control.

FINANCIAL INFORMATION

The Board hereby announces the consolidated audited results of the Group for the year ended December 31, 2024 with comparative figures for the year ended December 31, 2023 as follows:

CONSOLIDATED INCOME STATEMENT

	Note	**Year Ended December 31, 2024** *RMB'000*	Year Ended December 31, 2023 *RMB'000*
Revenue	*4*	**551,156**	573,137
Cost of sales	*5*	**(326,213)**	(394,135)
Gross profit		**224,943**	179,002
Selling expenses	*5*	**(87,571)**	(150,207)
Administrative expenses	*5*	**(321,415)**	(268,913)
Research and development expenses	*5*	**(87,054)**	(169,191)
Net impairment losses on financial and contract assets		**(3,591)**	(8,402)
Net impairment losses on intangible assets		**(9,795)**	(9,572)
Other income		**18,020**	19,419
Other gains – net		**14,011**	11,277
Operating loss		**(252,452)**	(396,587)
Finance income		**35,774**	41,654
Finance cost		**(727)**	(1,431)
Finance income – net		**35,047**	40,223
Loss before income tax		**(217,405)**	(356,364)
Income tax expenses	*6*	**–**	(15)
Loss for the year		**(217,405)**	(356,379)
Loss attributable to:			
Owners of the Company		**(214,609)**	(346,778)
Non-controlling interests		**(2,796)**	(9,601)
		(217,405)	(356,379)
Loss per share for loss attributable to owners of the Company			
Basic and diluted loss per share (RMB)	*7*	**(0.39)**	(0.64)

CONSOLIDATED STATEMENT OF COMPREHENSIVE LOSS

	Year Ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
Loss for the year	**(217,405)**	(356,379)
Other comprehensive (losses)/income		
Item that may be reclassified to profit or loss		
Exchange differences on translation of foreign operations	**(4,271)**	1,866
Other comprehensive (losses)/income for the year, net of taxes	**(4,271)**	1,866
Total comprehensive loss for the year	**(221,676)**	(354,513)
Total comprehensive loss for the year attributable to:		
Owners of the Company	**(218,839)**	(344,902)
Non-controlling interests	**(2,837)**	(9,611)
	(221,676)	(354,513)

CONSOLIDATED BALANCE SHEET

	Note	As at December 31, 2024 RMB'000	As at December 31, 2023 RMB'000
ASSETS			
Non-current assets			
Property, plant and equipment		**12,201**	21,942
Right-of-use assets		**23,003**	19,347
Intangible assets		**58,181**	72,191
Restricted cash		**–**	5,000
Long-term receivables	*10*	**12,712**	–
		106,097	118,480
Current assets			
Contract fulfilment cost		**3,546**	14,024
Contract assets		**16,614**	21,419
Trade and notes receivables	*9*	**170,013**	146,257
Other receivables and prepayments		**82,444**	74,998
Financial assets at fair value through profit or loss		**120,792**	280,826
Short-term treasury investments		**159,374**	–
Short-term bank deposits		**599,920**	269,233
Restricted cash		**5,100**	1,511
Cash and cash equivalents		**319,297**	517,924
		1,477,100	1,326,192
Total assets		**1,583,197**	1,444,672
EQUITY			
Equity attributable to owners of the Company			
Share capital		**563,779**	538,000
Other reserves		**2,295,189**	1,922,646
Currency translation reserves		**1,919**	6,149
Accumulated losses		**(1,703,077)**	(1,488,468)
		1,157,810	978,327
Non-controlling interests		**76,763**	63,786
Total equity		**1,234,573**	1,042,113

	Note	As at December 31, 2024 RMB'000	2023 RMB'000
LIABILITIES			
Non-current liabilities			
Lease liabilities		**13,283**	2,781
Deferred revenue		**7,402**	8,174
Warrant liabilities		**35,347**	33,735
		56,032	44,690
Current liabilities			
Borrowings		**10,004**	–
Trade and other payables	*11*	**184,418**	208,176
Lease liabilities		**11,471**	12,308
Contract liabilities		**86,699**	137,385
		292,592	357,869
Total liabilities		**348,624**	402,559
Total equity and liabilities		**1,583,197**	1,444,672
Net current assets		**1,184,508**	968,323
Total assets less current liabilities		**1,290,605**	1,086,803

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

1 General information

The Group is primarily engaged in providing digital solutions for life sciences R&D and commercialisation mainly in the PRC and certain overseas countries and regions.

The ultimate controlling shareholder of the Group is Mr. ZHAO Lu (趙璐).

On October 8, 2024, the Company completed the Global Offering and was successfully listed on Main Board of The Stock Exchange of Hong Kong Limited.

2 Basis of preparation and changes in accounting policy and disclosures

2.1 Basis of preparation

(a) Compliance with IFRS Accounting Standards (IFRS)

The consolidated financial statements of the Group have been prepared in accordance with IFRS and interpretations issued by the IFRS Interpretations Committee ("**IFRS IC**") applicable to companies reporting under IFRS. The financial statements comply with IFRS as issued by the International Accounting Standards Board ("**IASB**") and the disclosure requirements of Hong Kong Companies Ordinance Cap. 622.

The preparation of the consolidated financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements.

(b) Historical cost convention

The consolidated financial statements have been prepared under the historical cost convention, except for the following:

- certain financial assets and liabilities (including derivative instruments) – measured at fair value; and
- contingent consideration – measured at fair value

2 Basis of preparation and changes in accounting policy and disclosures (continued)

2.2 Changes in accounting policy and disclosures

(a) Amended standards adopted by the Group

The Group has applied the following standards and amendments for the first time for its financial year commencing January 1, 2024:

- Amendments to IAS 1 — Classification of Liabilities as Current or Non-current, Non-current Liabilities with Covenants
- Amendments to IFRS 16 — Lease liability in sale and leaseback
- Amendments to IAS 7 and IFRS 7 — Supplier Finance Arrangements

The amendments listed above did not have any material impact on the amounts recognised in prior years and are not expected to significantly affect the current or future years.

(b) New standards and amendments not yet adopted

The followings are new standards and amendments that have been issued but are not effective for the year ended December 31, 2024, and have not been early adopted by the Group. The Group plans to adopt these new standards and amendments when they become effective:

Standards and amendments		**Effective for accounting Periods beginning on or after**
IAS 21 (Amendment)	Lack of Exchangeability	January 1, 2025
IFRS 7 and IFRS 9 (Amendment)	Amendments to the Classification and Measurement of Financial Instruments	January 1, 2026
Annual Improvements to IFRS	Annual Improvements to IFRS Accounting Standards	January 1, 2026
IFRS 19	Subsidiaries without public accountability: disclosures	January 1, 2027
IFRS 18	Presentation and disclosure in financial statements	January 1, 2027

According to the assessment made by the directors of the Company, these new standards and amendments are either not relevant to the Group or not significant to the financial performance and positions of the Group when they become effective.

3 Segment information

The Group's business activities are mainly in providing cloud-based software products including SaaS products and customised products, digital services and others, for which discrete financial information is available, are regularly reviewed and evaluated by the executive directors of the Company, who are the chief operating decision makers. As a result of this evaluation, the executive directors of the Company consider that the Group's operation is operated and managed as a single segment and no segment information is presented, accordingly.

For the year ended December 31, 2024, there was no revenue derived from transactions with a single external customer which amounted to 10% or more of the Group's revenue.

(a) Geographical information

The Group mainly operates its businesses in mainland China. The following table shows the Group's total consolidated revenue by location of the customers during the year ended December 31, 2024:

	Year ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
Mainland China	**522,090**	567,569
Singapore	**20,034**	895
Korea	**5,298**	2,717
Others	**3,734**	1,956
	551,156	573,137

(b) Non-current assets

The total of the non-current assets including property, plant and equipment, right-of-use assets, and intangible assets as at December 31, 2024, broken down by the location of the assets, is as follows:

	As at December 31,	
	2024	2023
	RMB'000	*RMB'000*
Mainland China	**90,839**	107,927
Singapore	**1,296**	2,584
The United States	**1,250**	2,969
	93,385	113,480

4 Revenue

Revenue for the year ended December 31, 2024 is as follows:

	Year ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
Cloud-based software products		
– SaaS products	**161,926**	155,740
– Customised products	**46,685**	45,613
Digital services	**342,512**	369,931
Other services	**33**	1,853
	551,156	573,137

Disaggregation of revenue from contracts with customers by the timing of revenue recognition is as follows:

	Year ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
Recognised over time	**520,955**	545,832
Recognised at a point in time	**30,201**	27,305
	551,156	573,137

5 Expenses by nature

	Year ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
Employee benefit expenses (excluding share-based payments)	**363,852**	595,174
Clinical research related costs	**153,463**	167,457
Share-based compensation to certain shareholders	**92,836**	–
Share-based payments	**36,583**	13,292
Costs of IT infrastructure and data service	**32,871**	37,496
Listing expenses in relation to the Global Offering	**30,726**	14,005
Office, business development and travelling expenses	**26,976**	49,776
Depreciation of right-of-use assets	**20,760**	28,058
Consulting and professional service fees	**19,017**	15,632
Depreciation of property, plant and equipment	**14,971**	19,849
Amortisation of intangible assets	**4,215**	4,055
Listing expenses in relation to previous listing preparation	**–**	12,016
Short-term rental expenses	**799**	3,514
Auditor's remuneration		
– Audit services	**2,800**	–
Other expenses	**22,384**	22,122
	822,253	982,446

6 Income tax expenses

	Year ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
Current income tax	**–**	15
Deferred income tax	**–**	–
Income tax expense	**–**	15

7 Loss per share

Basic

The basic loss per share is calculated by dividing the loss attributable to owners of the Company by the weighted average number of ordinary shares in issue during the year ended December 31, 2024.

	Year ended December 31,	
	2024	2023
Loss attributable to owners of the Company (RMB'000)	**(214,609)**	(346,778)
Weighted average number of ordinary shares in issue (thousand shares)	**543,916**	538,000
Basic loss per share (expressed in RMB per share)	**(0.39)**	(0.64)

Diluted

Diluted loss per share is calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares. As the Group incurred losses for the year ended December 31, 2024, the potential ordinary shares, i.e. restricted shares issued under the Company's and the subsidiary's share incentive plan, were not included in the calculation of diluted loss per share as their inclusion would be anti-dilutive. Accordingly, diluted loss per share for the year ended December 31, 2024 is the same as basic loss per share (2023: same as basic loss per share).

8. Dividends

No dividend had been declared or paid by the Company during the year ended December 31, 2024 (2023: nil).

9 Trade and notes receivables

	As at December 31,	
	2024	2023
	RMB'000	*RMB'000*
Notes receivables (a)	**1,958**	512
Provision for impairment	**–**	–
	1,958	512
Trade receivables (b)	**188,684**	162,909
Provision for impairment	**(20,629)**	(17,164)
	168,055	145,745
	170,013	146,257

(a) Notes receivables

The aging of notes receivables based on the receipt of the notes is within 180 days, which is within the Group's credit terms.

(b) Trade receivables

The credit terms given to trade customers are determined on an individual basis with normal credit period mainly around 30 to 120 days. The aging analysis of the trade receivables based on date of revenue recognition is as follows:

	As at December 31,	
	2024	2023
	RMB'000	*RMB'000*
Up to 3 months	**79,957**	75,749
3 months to 6 months	**38,446**	32,072
6 months to 1 year	**28,371**	30,773
1 to 2 years	**29,904**	19,500
2 to 3 years	**9,021**	3,566
More than 3 years	**2,985**	1,249
	188,684	162,909

10 Long-term receivables

Long-term receivables represented the receivables due for settlement by instalments, which are generally between 1 to 5 years. Long-term receivables contain significant financing components. Accordingly, these receivables are recognised initially at fair value and subsequently at amortised cost using the effective interest method. The portion due for settlement within 1 year is reclassified to trade receivables. The balance of long-term receivables was analysed in the following table.

	As at December 31,	
	2024	2023
	RMB'000	*RMB'000*
Payment by instalment sales contract	**15,529**	–
Less: due within one year	**(2,729)**	–
	12,800	–
Less: provision for impairment	**(88)**	–
	12,712	–

11 Trade and other payables

	As at December 31,	
	2024	2023
	RMB'000	*RMB'000*
Trade payables – third parties	**99,961**	70,720
Other payables – third parties	**9,210**	7,219
Payables for listing expenses in relation to the Global Offering	**1,486**	5,484
VAT payables related to contract liabilities	**6,188**	8,896
Staff salaries and welfare payables	**54,650**	100,261
Accrued taxes other than income tax	**5,765**	10,434
Provision for an outstanding litigation	**4,313**	1,000
Others	**2,845**	4,162
	184,418	208,176

Aging analysis of the trade payables based on purchase date is as follows:

	As at December 31,	
	2024	2023
	RMB'000	*RMB'000*
Up to 3 months	**54,715**	50,340
3 months to 6 months	**14,141**	8,757
6 months to 1 year	**13,858**	10,445
1 to 2 years	**17,088**	1,178
More than 2 years	**159**	–
	99,961	70,720

FINAL DIVIDEND

The Board does not recommend payment of a final dividend for the year ended December 31, 2024.

CORPORATE GOVERNANCE

The Group is committed to maintaining high standards of corporate governance to safeguard the interests of the Shareholders and to enhance corporate value and accountability. The Company has adopted the principles and code provisions set out in the CG Code as set out in Part 2 of Appendix C1 to the Listing Rules as its own code to govern its corporate governance practices. For the period from the Listing Date up to December 31, 2024, the Company has complied with all applicable code provisions of the CG Code except for the deviations as explained below. The Company will continue to review and monitor its corporate governance practices to ensure compliance with the CG Code.

Under paragraph C.2.1 of the CG Code, the roles of chairman and chief executive should be separate and should not be performed by the same individual. During the period from the Listing Date up to December 31, 2024, Mr. ZHAO Lu ("**Mr. Zhao**") was the chairman of the Board and the general manager (equivalent to the chief executive officer) of the Company. With experience in the pharmaceutical and medical science industries and having joined the Group since January 2016, Mr. Zhao is in charge of strategic planning, execution, operation and overall management of the Group. Despite the fact that the roles of the chairman of the Board and the general manager of the Company were both performed by Mr. Zhao during the period from the Listing Date up to December 31, 2024, which constituted a deviation from paragraph C.2.1 of the CG Code during the Reporting Period, the Board considers that vesting the roles of both the chairman of the Board and the general manager in Mr. Zhao had the benefit of ensuring consistent leadership and more effective and efficient overall strategic planning of the Group. The balance of power and authority is ensured by the operation of the Board, the supervisory committee, and the senior management of the Company, each of which comprises experienced and diverse individuals. The Board currently comprises six executive Directors and three independent non-executive Directors. Therefore, the Board possesses a strong independence element in its composition.

Under paragraph C.5.1 of the CG Code, Board meetings should be held at least four times a year at approximately quarterly intervals with active participation of the majority of the Directors, either in person or through electronic means of communication. As the Company was only first listed on the Stock Exchange on October 8, 2024, no meeting was held by the Board during the period from the Listing Date up to December 31, 2024. The Company expects to continue to convene at least four regular meetings in each financial year at approximately quarterly intervals in accordance with code provision C.5.1 of the CG Code.

Under paragraph D.3.3 of the CG Code, members of the Audit Committee should liaise with the Board and senior management and the Audit Committee must meet, at least twice a year, with the auditors. As the Company was only first listed on the Stock Exchange on October 8, 2024, no meeting was held by the Audit Committee during the period from the Listing Date up to December 31, 2024. The Company expects to continue to convene at least two regular meetings in each financial year at approximately semi-annually intervals in accordance with code provision D.3.3 of the CG Code.

Under paragraph F.1.1 of the CG Code, an issuer should have a policy on payment of dividends. The Company currently expects to retain all future earnings for use in operation and expansion of our business, and currently does not have any dividend policy to declare or pay any dividends in the foreseeable future. The declaration and payment of any dividends in the future will be determined by the Board and subject to the articles of association of the Company and the Company Law of the PRC (《中華人民共和國公司法》), and will depend on a number of factors, including the Group's financial performance and business operation, capital requirements and contractual restrictions. No dividend shall be declared or payable except out of profits and reserves lawfully available for distribution. As confirmed by the legal adviser to the Company as to PRC laws, according to the PRC laws, any future net profit that the Company makes will have to be first applied to make up for its historically accumulated losses, after which the Company will be obliged to allocate 10% of its net profit to its statutory common reserve fund until such fund has reached more than 50% of its registered capital. The Company will therefore only be able to declare dividends after (i) all its historically accumulated losses have been made up for; and (ii) the Company has allocated sufficient net profit to its statutory common reserve fund as described above. The Board will review the Company's status periodically and consider adopting a dividend policy if and when appropriate.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code as set out in Appendix C3 to the Listing Rules as its own code of conduct regarding dealings by Directors, Supervisors, and the Group's senior management who, because of his/her office or employment, is likely to possess inside information in relation to the Company's securities.

Upon specific enquiries, all Directors and Supervisors have confirmed that they have complied with the Model Code from the Listing Date up to December 31, 2024. In addition, the Company is not aware of any non-compliance of the Model Code by the senior management of the Group from the Listing Date up to December 31, 2024.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES OF THE COMPANY

The H Shares of the Company were first listed on the Main Board of the Stock Exchange on October 8, 2024. During the period from the Listing Date to December 31, 2024, neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities.

AUDIT COMMITTEE

The Audit Committee has been established with written terms of reference in compliance with the Listing Rules and the CG code. The Audit Committee comprises three members, including three independent non-executive Directors, namely Mr. FUNG Che Wai Anthony, Dr. JIANG Xiao and Dr. LI Zhiguo. Mr. FUNG Che Wai Anthony, who holds the appropriate professional qualifications as required under Rules 3.10(2) of the Listing Rules, is the chairman of the Audit Committee.

The Audit Committee, together with the management, has reviewed the accounting policies and practices adopted by the Group, as well as the internal control matters. The Audit Committee has reviewed and considered that the annual financial results for the year ended December 31, 2024 are in compliance with the relevant accounting standards, rules and regulations, and appropriate disclosures have been duly made.

SCOPE OF WORK OF PRICEWATERHOUSECOOPERS

The figures in respect of the Group's results for the year ended December 31, 2024 as set out in this announcement have been agreed by the Group's external auditor, PricewaterhouseCoopers, to the amounts set out in the Group's audited consolidated financial statements for the year ended December 31, 2024. The work performed by PricewaterhouseCoopers in this respect did not constitute an assurance engagement in accordance with Hong Kong Standards on Auditing, Hong Kong Standards on Review Engagements or Hong Kong Standards on Assurance Engagements issued by the Hong Kong Institute of Certified Public Accountants and consequently, no assurance has been expressed by PricewaterhouseCoopers on this announcement.

EVENTS AFTER THE REPORTING PERIOD

Change of general manager

Due to work re-arrangement, Mr. ZHAO Lu, an executive Director, the chairman of the Board and the general manager of the Company, ceased to serve as the general manager of the Company with effect from February 11, 2025. Mr. Zhao has continued to serve as an executive Director and the chairman of the Board, primarily responsible for overall strategic planning and execution of the Group and development of the Group's overseas business. On February 11, 2025, the Board resolved to appoint Ms. WAN Yunyun as the general manager of the Company with effect from the same date. Following such appointment, Ms. WAN Yunyun would serve as the general manager, the president of the digital services division, a senior vice president and the chief commercial officer of the Company, primarily responsible for daily management and operation of the Group, as well as management and operation of the digital services division of the Group. For further details, please refer to the announcement of the Company dated February 11, 2025.

Appointment of members of Nomination Committee

In light of the consultation conclusions of "Review of Corporate Governance Code and Related Listing Rules" published by The Stock Exchange of Hong Kong Limited on December 19, 2024, and with regard to the actual circumstances of the Company, on March 24, 2025, Ms. NI Xiaomei (an executive Director) and Mr. FUNG Che Wai Anthony (an independent non-executive Director) have been appointed as members of the Nomination Committee, with effect from March 24, 2025. For further details, please refer to the announcement of the Company dated March 24, 2025.

ANNUAL GENERAL MEETING

The Company will hold the AGM on Friday, June 13, 2025. A notice of AGM will be published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.taimei.com), and dispatched to the Shareholders in the manner as required by the Listing Rules in due course.

CLOSURE OF REGISTER OF MEMBERS OF H SHARES AND ASCERTAINING OF ELIGIBILITY FOR ATTENDING THE AGM

The register of members of H Shares will be closed from Tuesday, June 10, 2025 to Friday, June 13, 2025, both days inclusive, during which no transfer of H Shares will be registered, in order to determine the holders of the H Shares who are entitled to attend and vote at the forthcoming AGM. To be eligible to attend and vote at the AGM, all properly completed transfer documents, accompanied by relevant share certificates, must be lodged with the Company's H share registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong no later than 4:30 p.m. on Monday, June 9, 2025 for registration.

PUBLICATION OF THE ANNUAL RESULTS AND 2024 ANNUAL REPORT

This annual results announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.taimei.com). The annual report of the Company for the year ended December 31, 2024, containing all the information required by the Listing Rules, will be published on the websites of the Stock Exchange and the Company in due course.

APPRECIATION

The Board would like to express its sincere gratitude to the Shareholders, management team, employees, business partners and customers of the Group for their continuous support and contribution to the Group.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions shall have the following meanings.

"AGM"	the forthcoming 2024 annual general meeting of the Company to be held on Friday, June 13, 2025
"Articles of Association"	the articles of association of the Company currently in force
"Audit Committee"	the audit committee of the Board
"Board"	the board of Directors
"China" or "the PRC"	the People's Republic of China excluding, for the purposes of this announcement, Hong Kong, the Macau Special Administrative Region of the People's Republic of China and Taiwan
"Company" or "our Company"	Zhejiang Taimei Medical Technology Co., Ltd. (浙江太美醫療科技股份有限公司), a joint stock company with limited liability incorporated in the PRC, the predecessor of which was Jiaxing Taimei Medical Technology Co., Ltd. (嘉興太美醫療科技有限公司), a limited liability company established in the PRC on June 6, 2013, and if the context requires, includes its predecessor
"CG Code"	the Corporate Governance Code as set out in Appendix C1 to the Listing Rules
"CRO"	a contract research organization, which provides professional services to pharmaceutical companies and research institutions during the drug development process through contractual agreements
"Director(s)"	the director(s) of our Company
"Domestic Share(s)"	ordinary share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, which are subscribed for in Renminbi

"Global Offering"	has the meaning ascribed thereto in the prospectus of the Company dated September 27, 2024
"Group", "our Group", "our", "we" or "us"	the Company and its subsidiaries, or any one of them as the context may require or, where the context refers to any time prior to its incorporation, the business which its predecessors or the predecessors of its present subsidiaries, or any one of them as the context may require, were or was engaged in and which were subsequently assumed by it
"H Share(s)"	overseas listed foreign invested ordinary share(s) in the ordinary share capital of our Company, with a nominal value of RMB1.00 each, which are listed on the Stock Exchange
"Hong Kong"	the Hong Kong Special Administrative Region of the People's Republic of China
"HKD" or "HK$"	Hong Kong dollars and cents respectively, the lawful currency of Hong Kong
"IFRS"	International Financial Reporting Standards
"IRC"	an independent reading center, which provides unbiased reviewing and analysis of clinical trial imaging data for accuracy and consistency
"Listing"	listing of the H Shares on the Main Board of the Stock Exchange
"Listing Date"	October 8, 2024, on which the H Shares were first listed and dealings in the H Shares first commenced on the Stock Exchange
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange (as amended, supplemented or otherwise modified from time to time)
"Main Board"	the stock market (excluding the option market) operated by the Stock Exchange which is independent from and operated in parallel with the GEM of the Stock Exchange
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules
"Nomination Committee"	the nomination committee of the Board
"Reporting Period"	the year ended December 31, 2024
"RMB" or "Renminbi"	Renminbi, the lawful currency of the PRC
"R&D"	research and development
"Share(s)"	ordinary share(s) in the capital of our Company with a nominal value of RMB1.00 each, comprising Domestic Shares and H Shares

"Shareholder(s)"	holder(s) of the Share(s)
"SMO"	a site management organization, which is a commercial entity that assists clinical trial sites in conducting specific operational tasks for clinical trials
"SaaS"	software-as-a-service
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"subsidiary(ies)"	has the meaning ascribed thereto under the Listing Rules
"Supervisor(s)"	the supervisor(s) of the Company
"U.S. dollars" or "USD" or "US$"	United States dollars, the lawful currency of the United States
"%"	percent

Note: The English translation of Chinese names of entities included in this annual report is prepared for identification purpose only.

By order of the Board
Zhejiang Taimei Medical Technology Co., Ltd.
Mr. ZHAO Lu
Chairman of the Board

Hong Kong, March 24, 2025

As at the date of this announcement, the Board comprises Mr. ZHAO Lu, Mr. MA Dong, Mr. ZHANG Hongwei, Mr. LU Yiming, Mr. HUANG Yufei and Ms. NI Xiaomei as executive Directors; and Dr. JIANG Xiao, Dr. LI Zhiguo and Mr. FUNG Che Wai Anthony as independent non-executive Directors.